DexCom, Inc. $DXCM Shares Sold by Qtron Investments LLC

Key Points

• Qtron Investments LLC has reduced its holdings in DexCom, Inc. by 52.7%, now owning 4,661 shares worth approximately $318,000 after selling 5,194 shares during the last quarter.
• Multiple other investors increased their positions, with Golden State Wealth Management LLC raising its stake by 211.2%, now owning 389 shares valued at $27,000.
• DexCom reported a 15.2% year-over-year revenue increase with $1.16 billion in revenue for the last quarter, exceeding analyst expectations; the earnings per share was $0.48, beating estimates by $0.03.

Qtron Investments LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 52.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,661 shares of the medical device company's stock after selling 5,194 shares during the quarter. Qtron Investments LLC's holdings in DexCom were worth $318,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Horizon Investments LLC boosted its position in shares of DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after acquiring an additional 123 shares in the last quarter. Nia Impact Advisors LLC boosted its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares in the last quarter. Wedbush Securities Inc. boosted its position in shares of DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after acquiring an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. boosted its position in shares of DexCom by 3.2% during the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after acquiring an additional 182 shares in the last quarter. Finally, Trivium Point Advisory LLC boosted its position in shares of DexCom by 6.1% during the 1st quarter. Trivium Point Advisory LLC now owns 3,455 shares of the medical device company's stock worth $236,000 after acquiring an additional 200 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DXCM traded up $1.64 on Friday, hitting $82.26. 3,666,928 shares of the company traded hands, compared to its average volume of 4,009,486. The company has a 50 day moving average of $82.81 and a 200-day moving average of $79.89. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $32.26 billion, a PE ratio of 57.13, a PEG ratio of 1.69 and a beta of 1.43. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm's revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at $2,766,430.80. The trade was a 9.90% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,906 shares of company stock worth $1,832,451. Company insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several analyst reports. Barclays upped their price objective on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Piper Sandler boosted their target price on DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a report on Thursday, July 31st. Citigroup reissued a "buy" rating and issued a $102.00 target price (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Truist Financial began coverage on DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 target price for the company. Finally, Robert W. Baird reduced their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.